ridaforolimus + bevacizumab

Ridaforolimus + bevacizumab is an investigational combination therapy comprising ridaforolimus, an oral small-molecule inhibitor of mammalian target of rapamycin (mTOR), and bevacizumab, a monoclonal antibody that binds and neutralizes vascular endothelial growth factor A (VEGF-A). Ridaforolimus inhibits mTOR, a central regulator of cell growth and proliferation, leading to downstream inhibition of cancer cell survival and angiogenesis. Bevacizumab prevents VEGF-mediated signaling, reducing tumor vascularization. Clinical studies have focused on advanced, refractory solid tumors, particularly in patients resistant to standard therapies. The combination has demonstrated feasibility with manageable toxicity, but careful patient selection is necessary due to the risk of serious adverse events such as bowel perforation, attributed mainly to bevacizumab. The primary mechanism is dual inhibition of tumor angiogenesis and cell proliferation pathways, potentially overcoming resistance to anti-angiogenic therapy[1][2][5].

Other names

ridaforolimus + bevacizumab